+------------------------------------------------------------------------------+
KKR Eyes Spanish Lenders, May Seek Role Managing Bad Bank Assets 2014-05-13 06:25:39.30 GMT
By Sharon Smyth and Charles Penty May 13 (Bloomberg) -- KKR, the private-equity firm run by billionaires Henry Kravis and George Roberts, is interested in investing in a Spanish lender and may seek to manage assets of the country’s bad bank. * “We would very much like to share in the capital of a financial institution and we are following the process of the restructuring of all the banks in detail,” said Jesus Olmos, the firm’s Spanish head, in an interview in Madrid; KKR would like to “be there” if opportunities arise in a second wave of consolidation among former savings banks, he said
For Related News and Information: Sareb Said to Seek Companies to Manage $68.8 Billion of Assets NSN N3PLGI6VDKHY <GO> KKR to Apollo Vie for Spain Lending Left by Banks: Euro Credit NSN MTF14B6K50XW <GO>
To contact the reporter on this story: Charles Penty in Madrid at +34-91-700-9654 or cpenty@bloomberg.net To contact the editors responsible for this story: Frank Connelly at +33-1-5365-5063 or fconnelly@bloomberg.net Steve Bailey
2014-05-13 00:52:21.616 GMT
(Updates with tax benefit in seventh paragraph.)
By David Welch, Albertina Torsoli and Manuel Baigorri
May 13 (Bloomberg) -- Pfizer Inc. is planning to sweeten
its bid for U.K. rival AstraZeneca Plc for a second time, people
with knowledge of the matter said.
Pfizer and its advisers are crafting a new offer that would
increase the value modestly above the current 50 pounds-a-share
(about $84) level while bumping the cash portion, said two of
the people, who asked not to be identified discussing private
information. Pfizer will probably wait until after U.K.
government hearings to raise its bid, they said.
Pfizer is putting together a sweetened offer before it
considers whether to make a hostile takeover attempt by bringing
its proposal directly to AstraZeneca’s shareholders, the people
said. Pfizer would prefer a friendly deal since its unsolicited
overture already has attracted political scrutiny in the U.S.
and U.K. AstraZeneca rejected Pfizer’s second proposal on May 2,
valued at 62.6 billion pounds ($106 billion) and made up of 32
percent cash and the rest in stock.
Ian Read, Pfizer’s chief executive officer, and Pascal
Soriot, his counterpart at AstraZeneca, will testify at two
separate parliamentary committees this week, as the U.K.
government seeks guarantees that Pfizer will preserve jobs and
medical research in Britain.
Pfizer is concerned it’s beginning to lose momentum on the
deal, said two of the people, and will be talking further to
investors and listening to what comes out of the hearings as it
evaluates its next steps.
Representatives for Pfizer and AstraZeneca declined to
comment.
Tax Rates
Pfizer has said it would move its legal residence to the
U.K., gaining a lower tax rate, while the company’s operational
headquarters would remain in New York. In doing so, Pfizer would
join more than a dozen other companies that have said they are
making or considering such transactions since 2012.
Read has said the tax benefits, the chance to avoid U.S.
taxes on $70 billion in cash built up overseas and AstraZeneca’s
promising cancer medicines are among the reasons Pfizer is
pursuing the deal.
The tax issue has sparked criticism from U.S. lawmakers,
including Senator Ron Wyden, an Oregon Democrat and chairman of
the Senate Finance Committee that oversees tax legislation.
Wyden said he may take up a proposal that would make it harder
for U.S. companies to shift their legal addresses to avoid
taxes.
Cancer Drug
A deal with AstraZeneca would help Pfizer add early-stage
drugs that use the body’s own immune cells to recognize and
attack tumors. Atop the list is MEDI4736, AstraZeneca’s immuno-
oncology drug expected to compete with experimental therapies
from drugmakers including Bristol-Myers Squibb Co., Merck & Co.
and Roche Holding AG.
British lawmakers earlier this month mobilized against
Pfizer’s attempt, demanding Business Secretary Vince Cable
secure assurances on jobs and research investment. Part of
Pfizer’s pitch to British officials is that AstraZeneca is a
global company and has substantial operations and people outside
the country, said one of the people.
About 40 percent of AstraZeneca’s revenue in 2013 came from
North America, and more than 30 percent from outside of Europe,
data compiled by Bloomberg show.
AstraZeneca Chairman Leif Johansson said the drugmaker will
return to growth as an independent company and listed the
reasons for rejecting the Pfizer offer in a video this month.
Among them: The bid “significantly undervalued” the company,
he said.
Job Assurances
Pfizer has pledged to keep at least one-fifth of the
combined companies’ research and development workers and
substantial manufacturing plants in the U.K. for at least five
years after a deal.
In the U.S., the governors of Maryland and Delaware have
asked for similar assurances, raising concerns that Pfizer would
reduce about 5,700 AstraZeneca jobs in their states as part of a
cost-cutting effort after the acquisition. Read wrote the
governor’s yesterday saying it was too soon in the effort to
gain AstraZeneca to discuss potential effects on jobs.
An acquisition of AstraZeneca would add to the $127 billion
of mergers among pharmaceutical companies this year, according
to data compiled by Bloomberg. An industrywide recalibration
that has been building since 2011 reached a peak last month with
a flurry of activity by GlaxoSmithKline Plc, Novartis AG and
Valeant Pharmaceuticals International Inc.
For Related News and Information:
AstraZeneca Pipeline Is Lottery Ticket in Pfizer’s Pursuit
NSN N5GYUY6S972K <GO>
Pfizer-AstraZeneca Deal May Harm Search for New Medicines
NSN N4Y3MD6JTSEL <GO>
Pfizer’s Bid May Have Been Invited by U.K.’s Tax Policy
NSN N4R75Q6KLVS1 <GO>
Top health stories:TOP HEA <GO>
Bloomberg Industries Research: BI PHRM <GO>
--With assistance from Naomi Kresge in Berlin, Drew Armstrong in
New York and Michelle Fay Cortez in Minneapolis.
To contact the reporters on this story:
David Welch in New York at +1-212-617-2788 or
dwelch12@bloomberg.net;
Albertina Torsoli in Geneva at +41-22-317-9202 or
atorsoli@bloomberg.net;
Manuel Baigorri in London at +44-20-3525-4457 or
mbaigorri@bloomberg.net
To contact the editors responsible for this story:
Mohammed Hadi at +1-212-617-2914 or
mhadi1@bloomberg.net
Elizabeth Wollman, Andrew Pollack
After Hours Summary: RAX +12.7%, HALO +12.0%, APRI +9.3%, FTEK -23.5%, RDEN -16.7% following earnings/guidance
After Hours Gainers: Companies trading higher in after hours in reaction to earnings: RAX +12.7%, HALO +12.0%, APRI +9.3%, TC +7.1%, OSIR +5.6%, HMIN +5.6%, MBI +4.1%, PTLA +3.6%, PVA +2.8%, MCK +2.7%, DTSI +2%, NOAH +1.9%, HEAR +1.3%, EVDY +1.2%, BWC +0.2%, PCYG +0.1%, TWOU +0.1%
Companies trading higher in after hours in reaction to news: HALO +12.0% (Data Monitoring Committee for Study 202 of PEGPH20 now supports continued enrollment of patients; co also reported earnings), APRI +9.3% (received FDA clearance to begin clinical trial of RayVa for secondary Raynaud's phenomenon; co also reported earnings), DTV +6.1% (Bloomberg reporting that co and AT&T (T) are in talks of a deal for DTV to be acquired for ~$100 per share), ANR +1.3% (announced offering of $400 mln senior secured second lien notes), XOXO +1.1% (Becker Drapkin confirmed 7.2% stake in 13D filing; intends to engage company and may nominate or recommend candidates for the Board)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings: FTEK -23.5%, RDEN -16.7%, OESX -13.1%, KIN -8.9%, CALL -6.5%, CWCO -5.9%, DARA -3.7%, ARNA -3.2%, VGR -3.2%, RICK -2.2%, HASI -1.9%, RMTI -1.4%, ONTX -1.3%, APP -1.3%, LMNS -1.3%, DQ -0.7%, TCRD -0.5%, FENG -0.4%
Companies trading lower in after hours in reaction to news: BIOF (received a letter from the Listing Qualifications Staff; continued listing of its securities is no longer warranted), FNHC -4.7% (filed for $50 mln mixed securities shelf offering), OKS -3.9% (announced public offering of 11 mln of common units), IDRA -3.5% (filed for $200 mln mixed securities shelf offering), NRF -2.2% (announced public offering of 30 mln shares of common stock), AR -1.5% (announced secondary public offering of 10 mln shares common stock by Antero Resources Investment), DQ -0.7% (announced proposed follow-on public offering of 2 mln ADSs)
Asian Market Update: Australia property sector growth slows; China weakens CNY further despite the visit from Lew
***Economic Data*** - (AU) AUSTRALIA Q1 HOUSE PRICE INDEX Q/Q: 1.7% (1-year low) V 3.0%E; Y/Y: 10.9% V 10.4%E - (AU) AUSTRALIA MAR HOME LOANS M/M: -0.9% V +1.0%E; INVESTMENT LENDING: -0.8% V +4.4% PRIOR; OWNER-OCCUPIED LOAN VALUE: -1.2% V +1.8% PRIOR - (NZ) NEW ZEALAND APR FOOD PRICES M/M: +0.6% V -0.3% PRIOR (1st rise in 3 months) - (NZ) NEW ZEALAND APR ANZ TRUCKOMETER HEAVY M/M: +0.5% V -1.0% PRIOR - (JP) JAPAN APR MONEY STOCK M2 Y/Y: 3.4% V 3.4%E (one-year low); M3 Y/Y: 2.8% V 2.8%E - (UK) UK APR BRC SALES LFL Y/Y: 4.2% V 1.6%E (1st rise in three months; 3-year high)
Market Snapshot (as of 03:30 GMT): - Nikkei225 +1.7%, S&P/ASX +0.7%, Kospi +0.9%, Shanghai Composite flat, Hang Seng +0.2%, Jun S&P500 +0.1% at 1,894, Jun gold -0.2% at $1,293, Jun crude oil -0.1% at $100.54/brl
***Highlights/Observations/Insights*** - China markets are slightly more subdued after outsized gains overnight on reports of China State Council gradually relaxing FDI limits in listed companies. Economic data from China overnight were also mixed, with new Yuan loans missing estimates but M2 money supply growing above expectations. Investors await the release of the rest of April metrics - retail sales, industrial production, and FDI - later in today's session. In notable Chinese press, CSRC announced and additional 6 applicants for IPO, bringing the total pre-IPO disclosure filings to 319 since Apr 19th. On the currency front, PBoC once again set its Yuan midpoint at an 8-month low despite the impending visit from US Treasury Sec Lew, who is under increasing domestic pressure to take a more hard-line position on China's currency policy.
- Slowing growth in property prices in Australia may continue to soothe RBA worries of overheating in the sector, with Q1 house price index slowing to a 1-year low. Mortgage lending also turned negative on the month for the first time in 3 months. JPMorgan economist noted there has been a "deceleration from the euphoria that we saw in the second half of last year" and the economy is undergoing a "slower pace of demand filter through to house prices." Also note that Australia will unveil its annual budget - one of the toughest in govt's recent history - later in today's session.
- In M&A, shares of DTV were sharply higher afterhours after a press report suggested the company is in talks with AT&T over a $100/shr ($50B) deal. Separately, Pfizer was said to be looking to sweeten the cash component of its takeover bid for AstraZaneca and may present its new offer after UK parliamentary hearings. If rejected, Pfizer would reportedly consider a hostile takeover.
- Shares of Rusal are up nearly 3% in Hong Kong despite reporting a Q1 loss of $169M v profit $49M y/y. Rev also fell to $2.12B v $2.68B y/y, but the company forecasted a 6% rise in global aluminum demand in 2014 to 55Mt.
***Fixed Income/Commodities/Currencies*** - (JP) Japan MoF sells ¥545.9B in 1.7% (1.7% prior) 30-yr notes; Avg yield: 1.708% v 1.696% prior; Bid to cover: 4.62x v 2.93x prior - (CN) PBoC to drain CNY97B in 28-day repos (24th consecutive drain) - GLD: SPDR Gold Trust ETF daily holdings fall 2.4 tonnes to 780.5 tonnes (lowest since Jan 2009) - USD/CNY: (CN) PBoC sets yuan mid point at 6.1636 v 6.1625 prior setting (weakest since Sept 9th 2013)
***Equities*** US markets: - RAX: Reports Q1 $0.18 v $0.12e, R$421M v $420Me; +13.3% afterhours - DTV: Reportedly deal with AT&T being discussed is around $100/shr which would vale the deal at $50B - financial press; +5.9% afterhours - MBI: Reports Q1 $1.32 v $0.84 y/y, R$577M v $219M y/y; +3.9% afterhours - CVG: Reports Q1 $0.32 v $0.29e, R$606M v $548Me; Raises quarterly dividend 17% to $0.07 from $0.06; +3.5% afterhours - MCK: Reports Q4 $2.55 v $2.38e, R$38.1B v $35.2Be; +3.3% afterhours - AZN: Pfizer said to be raising cash part of bid; may consider going hostile if offer fails - financial press; +1.4% afterhours - TELK: MabVax Therapeutics and Telik Sign Definitive Merger Agreement; -4.6% afterhours - RDEN: Reports Q3 -$0.84 v $0.02e, R$210.8M v $256Me; Hires Goldman to advise on strategic alternatives; -16.7% afterhours
Notable movers by sector: - Financials: Ping An Insurance 2318.HK +1.0% (launches online financial product); Greentown China 3900.HK +2.3% (Apr sales results); Poly Property 119.HK +2.5% (Apr sales results) - Energy: Sinopec Shandong Taishan Petroleum 000554.CN +10.0%, Sinopec Shanghai Petrochemical 600688.CN +6.0% (PetroChina to sell Eastern Pipeline Co to public) - Industrials: Orica ORI.AU -5.4% (H1 results); China Resource Cement 1313.HK +2.7% (Q1 results); Shenzhen Auto Electric Power Plant 002227.CN +1.4%, BYD Corp 002594.CN +1.8% (China started construction of EV charging centers); Nissan Motor 7201.JP +4.5% (FY13/14 results); Isuzu Motors 7202.JP +5.7% (FY13/14 results); Mitsubishi Chemical Holdings 4188.JP +3.2% (plans to acquire Taiyo Nippon Sanso) - Technology: Square Enix Holdings 9684.JP +9.7% (analyst action); Sharp 6753.JP +5.4% (FY13/14 results)